ChinaBio Partnering Forum 2025
Shanghai, China 201204
Event summary
The ChinaBio Partnering Forum is one of the largest life sciences partnering conferences in China. This year’s event allowed delegates to identify, meet and network with leaders across the life sciences value chain – from global pharma and biotech companies to innovative startups and researchers from leading universities and institutes, along with VCs and other investors.
Cooley is proud to sponsor this year’s ChinaBio Partnering Forum and host two sessions discussing cross-border dealmaking.
For more information, please email Sandra Sun.
Featured agenda items
Wednesday, April 23, 2025 | 3:00 – 4:00 pm
Mastering Complex Landscapes: Strategic Collaborations and Cross-Border Transactions in Life Sciences
In today’s rapidly evolving life sciences sector, companies and investors face intricate challenges and opportunities in fundraising, collaborations and cross-border transactions. This session explored innovative strategies for navigating the complex landscapes to secure capital, maximize investment returns and drive successful business expansion. Industry insiders shared insights on structuring international partnerships, managing cross-border M&A and optimizing fundraising strategies for life sciences companies at various stages of growth.
Speakers
- Andrew Harline – Partner at Cooley
- Lila Hope – Partner at Cooley
- Rama Padmanabhan – Partner at Cooley
- Shawn Yu – Partner at Cooley
- Moderator: Christian Plaza – Partner at Cooley
Thursday, April 24, 2025 | 11:00 am – 12:00 pm
Unlocking the Potential of Newcos: Strategic Pathways to Success
In a competitive biotech environment, newly formed companies (Newcos) have the potential to disrupt the landscape with innovative solutions, but they also face unique challenges in securing investment and achieving growth. This panel brought together investors, biotech executives and industry professionals to discuss how Newcos can strategically position themselves to attract attention and capitalize on opportunities within the global and Chinese biotech ecosystems.
Speakers
- Kan Chen – Partner at Qiming Venture Partners
- Stella Shi – CEO and founder at Rona Therapeutics
- Jie Wu – Head of APAC at MPM BioImpact
- Shanshan Xu – CEO and founder at Bambusa Therapeutics
- Jieyu Zou – Partner at Lilly Asia Ventures
- Moderator: Yiming Liu – Partner at Cooley
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.